摘要
奥匹卡朋为一新的外周儿茶酚O-甲基转移酶抑制剂,于2016年6月获欧盟委员会批准,用于联合左旋多巴及多巴脱羧酶抑制剂治疗成人帕金森病和剂末症状波动患者。临床试验表明,奥匹卡朋50 mg·d-1的疗效明显优于安慰剂,而且不劣效于恩他卡朋。奥匹卡朋耐受性好,无严重肝功能损害。本文从药效学、药动学、临床疗效及不良反应等方面对奥匹卡朋进行了介绍。
Opicapone is a new peripheral catechol O-methyltransferase inhibitor.It was approved by European Commission in June 2016 as adjunctive treatment to levodopa-decarboxylase inhibitor therapy in adults with Parkinson disease and end-of-dose motor fluctuations.During the clinical trial,adjunctive opicapone 50 mg once daily provided significantly greater improvements in motor fluctuations than placebo,with these improvements noninferior to those with entacapone.Opicapone was generally well tolerated,with no serious cases of hepatotoxicity reported in clinical trials.This article summarized the pharmacodynamics,pharmacokinetics,clinical efficacy and adverse reactions of opicapone.
作者
杨君义
YANG Jun-yi(Department of Pharmacy, Central Hospital of Linyi City, Yishui SHANDONG 276400, Chin)
出处
《中国新药与临床杂志》
CSCD
北大核心
2017年第10期579-582,共4页
Chinese Journal of New Drugs and Clinical Remedies
